Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités

EarningsKangyuedaNeutral

AI Analysis

Summary

Keymed Biosciences reported first half 2026 results with total revenue of 617 million RMB, with flagship product Kangyueda contributing to revenue generation.

Financial Highlights

Revenue

617 million RMB

Importance:2/10

Sentiment:

0.00

earningsH1 2026revenueChinaHKEX

Related Companies

$2162

Read the original article

Published by PR Newswire Biotech on August 25, 2026 6:06 AM

Read Original